Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group-Reference-Cited by-同舟云学术

Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

Published:2003-12 Issue:12 Volume:14 Page:1762-1767
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Baetz T.,Belch A.,Couban S.,Imrie K.,Yau J.,Myers R.,Ding K.,Paul N.,Shepherd L.,Iglesias J.,Meyer R.,Crump M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/14/12/1762/395908/mdg496.pdf

Reference35 articles.

1. Hodgkin’s disease;DeVita;N Engl J Med,1993

2. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD;Canellos;N Engl J Med,1992

3. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial;Duggan;J Clin Oncol,2003

4. Current clinical trials for the treatment of advanced-stage Hodgkin’s disease: BEACOPP;Franklin;Ann Oncol,2002

5. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease;Yuen;Blood,1997

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06

2. Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy – A case report and literature review;Acta Paediatrica;2024-04-10

3. Pediatric Hodgkin Lymphoma;Tata Memorial Centre Textbook of Oncology;2024

4. Hematopoietic Cell Transplantation for Hodgkin Lymphoma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

5. The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure;Hematology;2023-12-08